



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Control of common viral epidemics but not of SARS-CoV-2 through the application of hygiene and distancing measures

Audrey Giraud-Gatineau^{a,b,c,d}, Lancei Kaba^{a,b,e}, Céline Boschi^{a,d,e}, Christian Devaux^{a,e,f}, Jean-Paul Casalta^{a,d,e}, Philippe Gautret^{a,b,d}, Hervé Chaudet^{a,b,c,d}, Philippe Colson^{a,d,e}, Didier Raoult^{a,e,*}

^a IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005, Marseille, France

^b Aix Marseille Univ, Institut de Recherche pour le Développement (IRD), Assistance Publique – Hôpitaux de Marseille (AP-HM), Service de Santé des Armées (SSA), Vecteurs – Infections Tropicales et Méditerranéennes (VITROME), 27 boulevard Jean Moulin, 13005, Marseille, France;

^c French Armed Forces Center for Epidemiology and Public Health (CESPA), Service de Santé des Armées (SSA), camp de Sainte Marthe, BP 40026, Marseille, France

^d Assistance Publique- Hôpitaux de Marseille (AP-HM), 264 rue Saint-Pierre, 13005, Marseille, France

^e Aix-Marseille Univ, Institut de Recherche pour le Développement (IRD), Assistance Publique - Hôpitaux de Marseille (AP-HM), Microbes Evolution Phylogeny and Infections (MEPHI), 27 boulevard Jean Moulin, 13005, Marseille, France

^f Centre National de la Recherche Scientifique (CNRS), Marseille, France

ARTICLE INFO

Key words:

Coronavirus
Respiratory infections
Gastrointestinal infections
SARS-CoV-2
MIDaS
Epidemic
Surveillance

ABSTRACT

Background: We systematically survey respiratory and gastrointestinal infections of viral origin in samples sent to our university hospital institute in Marseille, southern France. Here, we evaluated whether the measures implemented to fight COVID-19 had an effect on the dynamics of viral respiratory or gastrointestinal infections. **Methods:** We analysed PCR performed and positive for the diagnoses of viral respiratory and gastrointestinal infections over five years (January 2017-February 2021). Data were collected from our epidemiological surveillance system (MIDaS). Dates and contents of French measures against SARS-CoV-2 were collected from: <https://www.gouvernement.fr/info-coronavirus/les-actions-du-gouvernement>.

Results: Over the 2017-2021 period, 990,364 analyses were carried out for respiratory infections not including SARS-CoV-2, 510,671 for SARS-CoV-2 and 27,719 for gastrointestinal infections. During winter 2020-2021, when the most restrictive lockdown measures were in place in France, a marked decrease of infections with influenza viruses (one case versus 1,839-1,850 cases during 2017-2020 cold seasons) and with the RSV (56 cases versus 988-1,196 cases during 2017-2020 cold seasons) was observed, demonstrating the relative effectiveness of these measures on their occurrence. SARS-CoV-2 incidence seemed far less affected. Rhinoviruses, parainfluenza 3 virus, and the coronavirus NL63 remained at comparable levels. Also, the norovirus winter season positivity rates decreased continuously and significantly over time from 9.3% in 2017-2018 to 2.0% in 2020-2021.

Conclusion: The measures taken to control COVID-19 were effective against lower respiratory tract infections viruses and gastroenteritis agents, but not on the agents of the common winter cold and SARS-CoV-2. This suggests that more specific measures to prevent COVID-19 and upper respiratory tract infections need to be discovered to limit the spread of this epidemic.

1. BACKGROUND

In December 2019, a new coronavirus named SARS-CoV-2 (for severe acute respiratory syndrome coronavirus 2) emerged in Wuhan, Hubei region, China. It spread rapidly to the rest of the world and was declared a pandemic in March 2020 [1]. As of February 09, 2022 402,064,265 SARS-CoV-2 cases and 5,768,927 patient deaths from

COVID-19 (for coronavirus disease 2019) were reported [2]. SARS-CoV-2 variants have emerged since summer of 2020 [3,4] and have each determined an epidemic of variable intensity and duration. These variants have been revealed to be associated with differences regarding viral loads, transmissibility, and clinical severity and they have been involved in various degrees of escape to immunity elicited by vaccination or infection [5-8]. The dynamics of SARS-CoV-2 epidemics

* Corresponding author: Didier Raoult, IHU Méditerranée Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France

E-mail address: didier.raoult@gmail.com (D. Raoult).

<https://doi.org/10.1016/j.jcv.2022.105163>

Received 18 April 2021; Received in revised form 12 March 2022;

Available online 16 April 2022

1386-6532/© 2022 Elsevier B.V. All rights reserved.

at national and global scales proved to be unpredictable.

In order to reduce the spread of SARS-CoV-2, the French government decided to take several health and social measures. This initially involved repeated risk prevention messages on the use of protective measures including regularly hand washing with soap or alcohol-based hand gel, social distancing of 1.5 meter between individuals, and wearing a mask [9]. These measures had already been used in prevention campaigns for other viruses, particularly respiratory viruses such as influenza [10,11]. More restrictive measures on movement were also taken, with the implementation of a number of lockdowns and curfews (Decree No. 2020–260; Decree No. 2020–1310) [12,13]. Thus, in addition to the fight against COVID-19, these measures may also be effective at controlling other communicable respiratory and digestive diseases.

At the Hospital University Institute Méditerranée Infection (IHU-MI), the activity of the virology and microbiology laboratory is monitored by a collection and surveillance system known as MIDaS (for Méditerranée Infection Data Warehousing and Surveillance) [14,15]. This system enables us to monitor respiratory and digestive virus infections on a weekly basis, and has included COVID-19 since its emergence in France [16]. The objective of this study was to analyse the epidemiological curves of respiratory and gastrointestinal viruses since the emergence of SARS-CoV-2 and to evaluate if they changed under the measures implemented against COVID-19 in France by comparing them during cold seasons over the past five years.

2. MATERIALS AND METHODS

2.1. Surveillance system

Since 2003, the activity of our clinical microbiology laboratory has involved massive and unbiased monitoring of all clinical samples received for testing bacteria, viruses, parasites and microscopic fungi [16,17]. This followed recommendations from one of the authors (DR) [18] made to the French government in 2003 to set up surveillance systems of any abnormal events related to infectious diseases based on laboratory data, including through syndromic surveillance. Our laboratory is the single one to diagnose infections for all public university hospitals (Assistance Publique - Hôpitaux de Marseille (AP-HM)) in Marseille, which have a total of 3,288 beds with nearly 125,000 admissions and one million consultations per year. Our laboratory conducts approximately eight million tests every year.

Since 2013 when the IHU-MI was established, our surveillance tools have expanded further and have improved through our unique MIDaS (for Méditerranée Infection Data Warehousing and Surveillance) collection and surveillance system, which consists of five sub-systems [14]. We systematically collect all laboratory data (samples, tests, positive diagnoses) from the Nexlab laboratory management system. All microbiological analysis results (sample identification, requesting clinical department, date of sampling, analysis, result, antibiotic susceptibility testing, antibiotic resistance phenotype, bacterial co-identifications) and patient information (anonymised patient identification, age, sex, home postal code, anonymised hospital stay identification, date of stay within a department, death) are then deposited in a dedicated data warehouse. All clinical samples, tests and infectious agents are monitored on a weekly basis throughout the year. MIDaS automatically detects any aberrations in the statistical signal using the cumulative sum control chart (CUSUM) algorithm and triggers alarms [19]. These alarms are discussed during a weekly epidemiological staff meeting, which includes epidemiologists, biologists, and infectiologists.

Respiratory and gastrointestinal samples and infectious agents are some of the items surveyed. Respiratory and gastrointestinal viruses are diagnosed in our laboratory using commercial or in-house real-time Polymerase Chain Reaction (qPCR) tests and adopting a syndromic approach using multiplex or simplex tests. They included influenza A and B viruses, respiratory syncytial virus (RSV), rhinoviruses,

enteroviruses, adenoviruses, metapneumovirus, endemic coronaviruses (HCoV-OC43, -NL63, -E229 and -HKU1), parainfluenza viruses 1 to 4 (HPIV1 to HPIV4) and SARS-CoV-2, over a period of time from January 2017 to February 2021. For the detection of SARS-CoV-2 RNA, we used in house qPCR procedures previously described [20]. To detect the other respiratory viruses, we used the FTD Respiratory pathogens 21 (Fast Track Diagnosis, Luxembourg), the Biofire FilmArray Respiratory panel 2 plus (BioMérieux, Marcy-l'Etoile, France), the Respiratory Multi-Well System r-gene (BioMérieux), or the GeneXpert Xpert Flu/RSV (Cepheid, Sunnyvale, CA, USA) assays [21].

Data on diagnoses of influenza A and B viruses were also collected from a private clinical microbiology and virology laboratory through the PACASurVE (for the Provence Alpes-Côte d'Azur Surveillance Epidemiological System) network that extends our surveillance system to private medical biology laboratories located in the Provence Alpes-Côte d'Azur French region that includes Marseille [22]. These diagnoses were reached by an immunochromatographic assay in 2017 and then by the GeneXpert Flu/RSV assay between 2018 and 2021.

The gastrointestinal viruses diagnosed included adenoviruses, rotaviruses, sapoviruses, noroviruses and astroviruses. The tests were performed using the Fast Track Diagnosis viral gastroenteritis pathogens assay (Fast Track Diagnosis).

2.2. Statistical analyses

In order to better understand the evolution of respiratory and gastrointestinal virus infections over time, the proportion of positive results between October and the end of February were compared for each virus for the 2017–2018, 2018–2019, 2019–2020 and 2020–2021 seasons. These evolutions were analysed using the log-linear model, and the Fisher and Chi-square tests for point comparisons with a two-tailed statistical significance threshold of 0.05. Statistical analyses were done using R version 4.1 [23].

2.3. Government measures and policies

Measures taken by the French government in the fight against the spread of SARS-CoV-2 and dates when these measures were implemented were collected from the government website (<https://www.gouvernement.fr/info-coronavirus/les-actions-du-gouvernement>).

3. RESULTS

3.1. Diagnoses of respiratory viral infections at IHU-MI from 2017 to 2021

Over a period of five years (January 2017 to February 2021), 990,364 analyses were performed for common respiratory viruses, with 37,915 positive results. Most of these cases were due to influenza viruses (influenza A virus, 6,544; influenza B viruses, 2,459) followed by rhinoviruses (7,379), RSVs (3,846), adenoviruses (1,991), metapneumoviruses (1,482), enteroviruses (790), HCoV HKU1 (424), HCoV NL63 (421), HCoV OC43 (227), HCoV E229 (87), HPIV3 (340), HPIV4 (68), HPIV2 (18) and HPIV4 (9) (Table 1).

Slight yearly variations were observed from 2017 to 2019 with regards to the respective prevalence of these viruses (Fig. 1). In 2017, the influenza A virus was the most frequently identified respiratory viral agent (12.1%), followed by rhinovirus (9.3%) and RSV (7.2%). In the same year, 1.7% of samples tested for influenza B virus were positive for this agent. In 2018, the rhinovirus was the most commonly diagnosed (12.6%), compared to 6.9% for RSV, 6.3% for influenza A virus and 5.2% for influenza B virus. 2019 was comparable to 2017 in terms of the ranking of respiratory viruses, although the proportions of respiratory viruses' diagnoses were higher in 2019. The intensity of the epidemic peak for each of these respiratory viruses therefore changed over the years, as did the date upon which they appeared (Fig. 1).

Table 1 Tests performed and positive for PCR detection of respiratory viruses in 2017, 2018, 2019, 2020 and 2021 at Hospital University Institute Méditerranée Infection.

	2017		2018		2019		2020		2021		Total2017-2021							
	N	%	N	%	N	%	N	%	N	%	N	%						
Adenovirus	5,656	14,881	17,636	32,237	5,283	75,693	160	2.8	449	3.0	652	3.7	600	1.9	130	2.5	1,991	2.6
Common coronaviruses	2,395	3,773	8,211	32,237	5,283	51,899	70	2.9	110	2.9	231	2.8	998	3.1	276	5.2	1,685	3.2
HCoV 229E	2,395	3,773	8,211	11,739	5,283	31,401	0	0.0	0	0.0	0	0.0	84	0.7	3	0.1	87	0.3
HCoV HKU1	2,395	3,773	8,211	11,736	5,283	31,398	0	0.0	0	0.0	0	0.0	423	3.6	1	0.4	424	1.4
HCoV NL63	3,791	3,773	8,211	11,739	5,283	32,797	0	0.0	0	0.0	0	0.0	252	2.1	169	3.2	421	1.3
HCoV OC43	9,007	3,773	8,211	11,74	5,283	38,014	0	0.0	0	0.0	0	0.0	175	1.5	102	1.9	277	0.7
Enterovirus	4,362	8,933	17,649	32,237	5,283	68,464	36	0.8	164	1.8	279	1.6	307	1.0	4	0.1	790	1.2
Influenza virus	12,992	14,856	17,844	32,237	5,283	83,212	1,737	13.4	1,708	11.5	2,427	13.6	3,119	9.7	0	0.0	8,991	10.8
Influenza A virus	12,608	14,859	17,847	32,237	5,283	82,834	1,525	12.1	936	6.3	2,397	13.4	1,686	5.2	0	0.0	6,544	7.9
Influenza B virus	13,088	14,858	17,847	32,237	5,283	83,313	222	1.7	772	5.2	30	0.2	1,435	4.5	0	0.0	2,459	3.0
Metapneumovirus	7,654	14,75	17,622	32,237	5,283	77,546	230	3.0	325	2.2	445	2.5	462	1.4	20	0.4	1,482	1.9
Human parainfluenza virus	9,007	3,771	8,268	32,237	5,283	58,566	15	0.2	200	5.3	438	5.3	129	0.4	322	6.1	1,104	1.9
HPV1	3,791	3,771	8,268	9,268	5,283	30,381	0	0.0	0	0.0	0	0.0	9	0.1	0	0.0	9	0.0
HPV2	3,791	3,771	8,268	9,268	5,283	30,381	0	0.0	0	0.0	0	0.0	17	0.2	1	0.0	18	0.1
HPV3	2,395	3,771	8,268	9,268	5,283	28,985	0	0.0	0	0.0	0	0.0	41	0.4	299	5.7	340	1.2
HPV4	2,395	3,771	8,268	9,268	5,283	28,985	0	0.0	0	0.0	0	0.0	48	0.5	20	0.4	68	0.2
Rhinovirus	4,305	14,057	17,637	32,237	5,283	73,519	401	9.3	1,771	12.6	2,264	12.8	2,494	7.7	449	8.5	7,379	10.0
Respiratory syncytial virus	12,756	14,849	17,851	32,237	5,283	82,976	923	7.2	1,024	6.9	1,347	7.5	498	1.5	54	1.0	3,846	4.6
SARS-CoV-2	0	0	0	420,120	90,551	510,671	0	0	0	0	0	0	26,723	6.4	8,236	9.1	34,959	6.8

HCoV, human coronavirus; HPIV, human parainfluenza virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

Since February 2020, 510,671 samples have been analysed for SARS-CoV-2 and 34,959 tested positive (6.8%). Of 420,120 samples tested for SARS-CoV-2 in 2020, 6.4% (N = 26,723) were positive while in 2021, out of 90,551 samples, 9.1% were positive. The government introduced several restrictive measures in an attempt to mitigate the spread of SARS-CoV-2 and to control the epidemic as effectively as possible. A first lockdown was imposed between 17 March 2020 and 11 May 2020, recommendations have been in place on wearing masks in enclosed spaces (particularly in the workplace) since 20 July 2020, a curfew was introduced between 8:00 pm and 6:00 am between 17 October 2020 and 28 October 2020, a second lockdown took place between 29 October 2020 and 15 December 2020, and a new curfew was introduced on 16 January 2021 from 6:00 pm to 6:00 am. In addition to these actions, individual preventive measures have also been recommended, including hand washing with soap or alcohol-based hand gel, a distance of 1.5 metres between individuals and the promotion of remote working. In 2020, the proportion of positive tests dramatically decreased to 7.7% for rhinoviruses, 5.2% for influenza A virus, 4.5% for influenza B virus and 1.5% for RSV. This was also the case for the first two months of 2021, where no cases of influenza A or B were observed. In the first two months of 2021, the most frequently diagnosed virus was SARS-CoV-2 (9.1%), followed by rhinoviruses (8.5%), parainfluenza viruses (6.1%, mainly HPIV3: 5.7%) and endemic coronaviruses (5.2%, mainly HCoV NL63: 3.2%). The same results regarding influenza A and B viruses were observed from a private clinical microbiology and virology laboratory through the PACASurV network (Table 2).

3.2. Comparison of winter seasons for respiratory viral infections

In order to avoid the Simpson effect, which is the presence of second order interactions between all factors that inverse statistical relations when data are pooled [24], we compared results during cold seasons (from October to mid-February). Over the last four such seasons, the most significant variations were observed for influenza A virus, with a positivity rate of 11.3% of the 9,819 tested samples (N= 1,106 cases) during the 2017–2018 winter season, which increased to 18.6% of the 10,973 tested samples (N= 2,042 cases) during the 2018–2019 season, dropped to 9.6% of the 11,711 tested samples (N= 1,125 cases) in 2019–2020 and accounted for 0% of the 8,786 tested samples in 2020–2021 (Fig. 1, Table 3). As of 24 February 2021, no cases of influenza A virus had been diagnosed during the 2020–2021 winter season. Influenza B virus was also absent for the 2020–2021 winter season, although this had already been observed in 2018–2019. RSV also showed a considerable decrease in the proportion of positive cases, reaching 0.6% (56 cases in 2020–2021 compared to between 9.4–10.9% (N= 988–1,196 cases) in the other three cold periods (p-value < 0.001). Metapneumovirus and enterovirus had a less marked decrease (N= 21 and 9 in 2020–2021 vs N= 339 and 375 in 2019–2020, respectively; p-value < 0.001). The adenovirus positivity rate has remained relatively constant over time, at about 3% (p-value > 0.05), as was the case for endemic coronaviruses in 2017–2018 and 2018–2019. A significant decrease was nevertheless observed in 2020–2021 (p-value < 0.001). Rhinovirus exhibited a significantly higher positivity rate in 2020–2021 (12.9%) compared to 2017–2019 and 2018–2019 (9.9% and 10.9% respectively, p-value < 0.001). The positivity rate of the HPIV3 parainfluenza virus increased from 0.1% (N = 4) in 2019–2020 to 3.7% (N = 324) in 2020–2021 (p-value < 0.001).

3.3. Total gastrointestinal viral infections at IHU-MI in 2017–2021

Between 2017 and 2021, 27,719 tests were performed resulting in approximately 1,098 diagnoses of gastrointestinal infections (Table 4). Rotavirus (5.6% for 6,612 samples analysed) was the most frequently diagnosed gastrointestinal virus over the study period, followed by adenovirus (5.2% for 6,227 samples analysed) and norovirus (4.2% for 7,791 samples analysed). As was previously observed for respiratory




Fig. 1. – Respiratory virus infections diagnosed at Hospital University Institute Méditerranée Infection in 2017–2021. Actions taken by the government are indicated by a dotted square for lockdowns, an arrow for the obligation to wear a mask in enclosed spaces, and a brace symbol for curfews.

Table 2

– Results for diagnoses of influenza A virus and influenza B virus by year for a private clinical microbiology and virology laboratory through the PACASurVe (for Provence Alpes-Côte d’Azur Surveillance Epidemiological System) network.

Year	Number of samples tested	Influenza A virus diagnoses		Influenza B virus diagnoses	
		N	%	N	%
2017	547	67	12.2	2	0.4
2018	1,111	63	5.7	29	2.6
2019	2,410	681	28.3	32	1.3
2020	2,625	500	19.0	357	13.6
2021	106	0	0.0	1	0.9

viruses, the intensity of the epidemic peak as well as the date of its onset varied over the years (Fig. 2). In 2017, 2018 and 2020, adenovirus was the most frequently identified virus (5.0%, 7.6% and 4.1% respectively) while in 2019, rotavirus (8.6%) was the virus most commonly identified.

In the first two months of 2021, of the 255 samples analysed, rotavirus was again the most frequently identified virus (N = 12, 4.7%) followed by norovirus (N = 10, 3.9%) and adenovirus (N = 10, 3.9%).

The overall positivity rate of gastrointestinal infections decreased significantly over time during the winter seasons (Table 5). Notably, the norovirus winter season positivity rates decreased continuously and significantly over time (2017–2018: 9.3%; 2018–2019: 8.4%; 2019–2020: 5.5%; 2020–2021: 2.0%). In contrast, adenovirus and rotavirus showed stable positivity rates between 2018–2019 (3.8% and 2.4% respectively) and 2020–2021 winter seasons (3.4% and 3.6% respectively) (Fig. 2).

4. DISCUSSION

In this study, the systematic monitoring of our microbiology and virology laboratory activity has enabled us to identify changes in the epidemiology of respiratory and gastro-intestinal viral communicable diseases during the spread of a new emerging virus, SARS-CoV-2.

These data show that the epidemiology of infection with SARS-CoV-2 is not at all similar to that of other respiratory infections. As observed in other countries and in France, flu viruses have decreased dramatically [25–27]. It should be noted that the number of infections by endemic coronaviruses and rhinoviruses does not seem to be particularly affected by the preventive measures taken and may have, in common with COVID-19, modes of transmission that are different from those of influenza viruses, RSV and the other respiratory viruses studied. Curiously, in our region, a higher number of parainfluenza virus 3 (HPIV3) were observed. One of the explanations for these epidemiological figures could be that the viruses experiencing a decrease in their incidence are most often involved in pneumonia, while, conversely, the agents responsible for nasal infections and for causing colds, such as endemic coronaviruses or HPIV3, remain constant. Measures to control COVID-19 would then prevent pneumonia, and gastroenteritis. From this hypothesis, it would be interesting to study the nasal and pneumonic forms in COVID-19 patients and assess their evolution in time.

The impact of measures to control COVID-19 probably played a major role in these epidemiological changes [28]. These measures included both repeated recommendations on risk prevention measures such as hand washing with soap or alcohol-based hand gel, disinfecting surfaces, and social distancing, but also actions which were legally enforced, including wearing masks and the implementation of lockdown or curfews [9,29]. Hand washing and disinfection was probably the main factor having an impact upon the usual respiratory and gastrointestinal viral infections [30], and have been key elements of influenza prevention campaigns for several years [11]. It is not clear from the literature that lockdown measures and other social control measures have really had an impact on the spread of SARS-CoV-2 or on other respiratory infections [31]. For example, Sweden has issued very few social control measures while other countries such as France have implemented relatively strong measures without significant differences in the number of cases or mortality [32].

The lack of effectiveness of these measures on the COVID-19 epidemic raises several questions. The first is the existence of infection

Table 3

- Tests performed and positive for PCR detection of respiratory viruses, during the same cold months in 2017–2018, 2018–2019, 2019–2020 and 2020–2021

Viruses	Tests				Positive											
	2017-2018	2018-2019	2019-2020	2020-2021	2017-2018			2018-2019			2019-2020			2020-2021		
	N	N	N	N	N	%	p value	N	%	p value	N	%	p value	N	%	
Adenovirus	8,876	10,831	11,687	8,786	262	3.0	0.51	416	3.8	0.006	355	3.0	0.74	274	3.1	
Common coronaviruses	387	1,123	11,556	8,786	13	3.4	0.97	37	3.3	0.96	617	5.3	<0.001	292	3.3	
HCoV 229E	387	1,123	6,357	8,786	0	0.0	1	0	0.0	1	31	0.5	<0.001	5	0.1	
HCoV HKU1	387	1,123	6,357	8,786	0	0.0	1	0	0.0	1	236	3.7	<0.001	1	0.0	
HCoV NL63	387	1,123	6,357	8,786	0	0.0	0.006	0	0.0	<0.001	114	1.8	0.49	171	1.9	
HCoV OC43	657	1,123	6,357	8,786	0	0.0	0.003	0	0.0	<0.001	56	0.9	0.02	114	1.3	
Enterovirus	900	10,83	11,688	8,786	13	1.4	<0.001	153	1.4	<0.001	375	3.2	<0.001	9	0.1	
Influenza virus	9,819	10,973	11,711	8,786	1,839	18.7	<0.001	2,044	18.6	<0.001	1,85	15.8	<0.001	1	0.0	
Influenza A virus	9,819	10,973	11,711	8,786	1,106	11.3	<0.001	2,042	18.6	<0.001	1,125	9.6	<0.001	0	0.0	
Influenza B virus	9,819	10,973	11,711	8,786	743	7.6	<0.001	2	0.0	1	727	6.2	<0.001	1	0.0	
Metapneumovirus	8,873	10,83	11,687	8,786	315	3.6	<0.001	258	2.4	<0.001	339	2.9	<0.001	21	0.2	
Human parainfluenza virus	657	1,127	11,605	8,786	4	0.6	<0.001	42	3.7	0.68	226	1.9	<0.001	350	4.0	
HPIV1	387	1,127	6,001	8,786	0	0.0	1	0	0.0	1	2	0.0	0.16	0	0.0	
HPIV2	387	1,127	6,001	8,786	0	0.0	1	0	0.0	1	4	0.1	0.17	1	0.0	
HPIV3	387	1,127	6,001	8,786	0	0.0	<0.001	0	0.0	<0.001	4	0.1	<0.001	324	3.7	
HPIV4	387	1,127	6,001	8,786	0	0.0	0.62	0	0.0	0.1	14	0.2	0.73	23	0.3	
Rhinovirus	5,15	10,833	11,683	8,786	511	9.9	<0.001	1,194	11.0	<0.001	1,42	12.2	0.11	1,134	12.9	
Respiratory syncytial virus	9,912	10,973	11,707	8,786	988	10.0	<0.001	1,196	10.9	<0.001	1,104	9.4	<0.001	56	0.6	
SARS-CoV-2	0	0	5,628	244,310	0	0.0	-	0	0.0	-	0	0.0	-	20748	8.5	

HCoV, human coronavirus; HPIV, human parainfluenza virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

Table 4

- Tests performed and positive for PCR detection of gastrointestinal viruses in 2017, 2018, 2019, 2020 and 2021 at Hospital University Institute Méditerranée Infection.

Viruses	Tests						Positive											
	2017	2018	2019	2020	2021	Total 2017-2021	2017		2018		2019		2020		2021		Total 2017-2021	
	N	N	N	N	N	N	N	%	N	%	N	%	N	%	N	%	N	%
Adenovirus	1,674	1,662	1,47	1,166	255	6,227	83	5.0	127	7.6	56	3.8	48	4.1	10	3.9	324	5.2
Astrovirus	0	886	1,458	1,146	255	3,745	0	0.0	18	2.0	16	1.1	6	0.5	0	0.0	40	1.1
Norovirus	1,386	1,666	2,368	2,116	255	7,791	60	4.3	91	5.5	101	4.3	63	3.0	10	3.9	325	4.2
Rotavirus	1,64	1,662	1,471	1,184	255	6,212	78	4.8	88	5.3	127	8.6	45	3.8	12	4.7	350	5.6
Sapovirus	0	886	1,46	1,143	255	3,744	0	0.0	12	1.4	38	2.6	8	0.7	1	0.4	59	1.6

outbreaks in animals which are distinct from outbreaks in humans. It has been demonstrated that the emergence of new variants could be promoted by the intensive captive breeding of certain animals such as mink, which are likely to contaminate humans by being potentially more contagious or more pathogenic for humans [34–36]. Furthermore, it seems likely that a certain number of treatments, including serotherapy with hyper-human sera and antivirals such as remdesivir, can promote the appearance of mutations [37].

Strong reductions in the incidence of some but not all respiratory viruses, and of viral agents of gastrointestinal infections have been also reported in several countries worldwide. This has been particularly noticed for influenza virus infections [28]. Tanislav and Kostev reported fewer non-SARS-CoV-2 respiratory tract infections and gastrointestinal infections during the SARS-CoV-2 pandemic [38]. They collected data from 994 general practitioners and 192 pediatricians in Germany and compared the prevalence of these infections between April 2020-March 2021 and April 2019-March 2020. Substantial falls (-71% for general practices and -90% for paediatrician practices) were observed for influenza virus infections, which was accompanied by a 40% fall of intestinal infections for general practices. Agca et al. reported, in a study on 319 nasopharyngeal samples in Turkey, a 7.5-fold reduction of the proportion of positive testing for influenza virus during March 2020-February 2021 compared to the previous year [2.3% (n= 9 cases) versus 17.3% (133), respectively] [39]. A significant reduction was also observed for other respiratory viruses including RSV but not for rhinoviruses/enteroviruses and metapneumovirus. Ippolito et al. also

reported in Italy a strong decrease during the SARS-CoV-2 pandemic of the diagnoses of several seasonal respiratory viruses among hospitalized children younger than two years [40]. Indeed, the number of positive tests was 80% lower during the September 2020-February 2021 period compared to between the same periods of years 2019-2020 and 2018-2019, with a disappearance of influenza viruses and RSV as well as disappearance or strong decreases of other respiratory viruses except rhinoviruses and endemic coronaviruses. In the Southern hemisphere, Yeoh et al., reported decreases by 99% and 98% of diagnoses of influenza viruses and RSV, respectively, in children in Western Australian through winter 2020 [41]. In Singapore, influenza virus positivity rate decreased by 64% during weeks 5–9 of 2020 compared with the preceding years [42].

The present study has several limitations. We focused on the epidemiology of respiratory and gastrointestinal viruses only over the last four cold seasons in our institute. We analyzed here a limited number of seasons but notwithstanding these data further support the unpredictability of the epidemiology of these viruses. We observed considerable variations from season to season throughout the respiratory virus epidemic period regarding the predominant viruses, the time of emergence and duration of winter epidemics, the level of incidence reached at the epidemic peaks, and the time at which this peak occurred [15]. Also, we acknowledge that estimating hospitalization pattern in the typical pre-SARS-CoV-2 season may be the subject of large random variation. Here, we have not analyzed the impact of respiratory viruses on hospital admissions, but their impact on hospital mortality has been




Fig. 2. – Gastrointestinal virus diagnosis between October 2017 and February 2021 at Hospital University Institute Méditerranée Infection. Comparison of winter seasons for gastrointestinal viral infections

Table 5

- Tests performed and positive for PCR detection of gastrointestinal viruses, during the same cold months in 2017–2018, 2018–2019, 2019–2020 and 2020–2021.

Viruses	Tests				Positive											
	2017-2018 N	2018-2019 N	2019-2020 N	2020-2021 N	2017-2018			2018-2019			2019-2020			2020-2021		
					N	%	p value	N	%	p value	N	%	p value	N	%	
Adenovirus	661	369	380	642	61	9.2	<0.001	14	3.8	0.8	31	8.2	0.001	22	3.4	
Astrovirus	0	369	368	619	0	0.0	-	6	1.6	0.003	5	1.4	0.01	0	0.0	
Norovirus	636	369	1026	664	59	9.3	<0.001	31	8.4	<0.001	56	5.5	<0.001	13	2.0	
Rotavirus	661	369	380	661	64	9.7	<0.001	9	2.4	0.3	5	1.3	0.03	24	3.6	
Sapovirus	0	369	369	619	0	0.0	-	5	1.4	0.03	8	2.2	0.002	1	0.2	

the subject of previous studies [15,33]. Finally, the present work has been conducted in a single institution, and the results could therefore display local specificities.

In conclusion, this study confirms that it is futile to try to make predictions about a disease for which the level of knowledge is limited [43]. The course of the epidemic over the past year was unpredictable and could not be integrated into any predictive models. Caution should be taken when using such models. Furthermore, this leads to the search for different modes of transmission of most respiratory diseases, as had already been mentioned in relation to SARS-CoV, where infections were retrospectively detected at a significant distance from the heart of the SARS-CoV outbreak, with no reasonable explanation [44]. Broad epidemiological surveillance of respiratory and gastrointestinal infections should be pursued in the future, as many changes occur during this pandemic among which public health policies and population behaviours including mask wearing or social distancing [31]. Also, in France, the issue of carriage and transmission by domestic pets has not been resolved and should be the subject of intense research to really understand the reservoirs, transmission and epidemiology of this very atypical virus. A new study on the 2021-2022 winter season should be carried out to better understand the epidemiology of these respiratory and gastrointestinal viruses and the impact of barrier measures on the spread of new SARS-CoV-2 variants with different transmissibility [45].

Author contributions

Conceived and designed the study: DR.; Collected data or/and performed experiments: AGG, LK, CB, JPC.; Analysed and interpreted data: AGG, CD, PC, PG, HC and DR.; Wrote the manuscript: AGG, PC, PG and DR.; All authors read and approved the final manuscript.

Ethics

All data have been generated as part of the routine work at Assistance Publique-Hôpitaux de Marseille (Marseille university hospitals), and this study results from routine standard clinical management. The study was approved by the ethical committee of the University Hospital Institute Méditerranée Infection (N°: 2020-029 and 2022-015). Access to the patients' biological and registry data issued from the hospital information system was approved by the data protection committee of Assistance Publique-Hôpitaux de Marseille (APHM) and was recorded in the European General Data Protection Regulation registry under number RGPD/APHM 2019-73.

Funding

This work was supported by the French Government under the "Investments for the Future" programme managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU-03, and was also supported by Région Provence Alpes Côte d'Azur and European funding FEDER PRIMMI (Fonds Européen de Développement Régional - Plateformes de Recherche et d'Innovation Mutualisées Méditerranée Infection), FEDER PA 0000320 PRIMMI.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.

References

- [1] B. Hu, H. Guo, P. Zhou, Z.L. Shi, Characteristics of SARS-CoV-2 and COVID-19, *Nat. Rev. Microbiol.* 19 (2021) 141–154, <https://doi.org/10.1038/s41579-020-00459-7>.
- [2] E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time, *Lancet Infect. Dis.* 20 (2020) 533–534, [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1).
- [3] P. Lemey, N. Ruktanonchai, S.L. Hong, et al., Untangling introductions and persistence in COVID-19 resurgence in Europe, *Nature* 595 (2021) 713–717, <https://doi.org/10.1038/s41586-021-03754-2>.
- [4] P. Colson, P. Fournier, H. Chaudet, et al., Analysis of SARS-CoV-2 variants from 24,181 patients exemplifies the role of globalization and zoonosis in pandemics, *Front. Microbiol.* 7 (2022), 786233, <https://doi.org/10.3389/fmicb.2021.786233>.
- [5] WT Harvey, AM Carabelli, B Jackson, et al., SARS-CoV-2 variants, spike mutations and immune escape, *Nat. Rev. Microbiol.* 19 (7) (2021 Jul) 409–424, <https://doi.org/10.1038/s41579-021-00573-0>.
- [6] J Li, S Lai, GF Gao, W Shi, The emergence, genomic diversity and global spread of SARS-CoV-2, *Nature* 600 (2021) 408–418, <https://doi.org/10.1038/s41586-021-04188-6>.
- [7] C Davis, N Logan, G Tyson, et al., Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination, *PLoS Pathog.* 2 (2021), e1010022, <https://doi.org/10.1371/journal.ppat.1010022>.
- [8] TL Dao, VT Hoang, P Colson, et al., SARS-CoV-2 infectivity and severity of COVID-19 according to SARS-CoV-2 variants: Current evidence, *J. Clin. Med.* 10 (2021) 2635, <https://doi.org/10.3390/jcm10112635>.
- [9] Information coronavirus, Les bons gestes à adopter, affiche – mesures barrières, February 25, 2021. Retrieved from, https://www.gouvernement.fr/sites/default/files/coronavirus-mesures_barrieres.pdf.
- [10] L. Canini, L. Andréoletti, P. Ferrari, et al., Surgical mask to prevent influenza transmission in households: a cluster randomized trial, *PLoS ONE* 5 (2010) e13998, <https://doi.org/10.1371/journal.pone.0013998>.
- [11] Santé Publique France, Prévenir la grippe saisonnière, Sept 2017. Retrieved February 25, 2021, from, <https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/documents/depliant-flyer/prevenir-la-grippe-saisonniere-septembre-2017>.
- [12] Decree No. 2020-260 of 16 March 2020 introducing regulations on movement in the context of the fight against the spread of COVID-19, <https://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000041728476>.
- [13] Decree No. 2020-1310 of 29 October 2020 prescribing general measures required to combat the COVID-19 epidemic in the context of the health emergency situation. <https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042475143?r=9BtQcTAF3G>.
- [14] L. Kaba, A. Giraud-Gatineau, MT. Jimeno, et al., Consequences of the COVID-19 Outbreak Lockdown on Non-Viral Infectious Agents as Reported by a Laboratory-Based Surveillance System at the IHU Méditerranée Infection, Marseille, France, *J. Clin. Med.* 10 (2021) 3210, <https://doi.org/10.3390/jcm10153210>.
- [15] P. Colson, A. Giraud-Gatineau, P.E. Fournier, et al., Epidemiological surveillance of respiratory viral infections at IHU Méditerranée Infection and its application to SARS-CoV-2, *IHU Preprint*, 2021, <https://doi.org/10.35088/gpgh-wq98>. Preprint.
- [16] C. Abat, H. Chaudet, P. Colson, et al., Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France, *Emerg. Infect. Dis.* 21 (2015) 1302–1310, <https://doi.org/10.3201/eid2108.141419>.
- [17] P. Colson, J.M. Rolain, C. Abat, et al., EPIMIC: A Simple homemade computer program for real-time EPIdemiological surveillance and alert based on MICrobiological Data, *PLoS ONE* 10 (2015), e0144178, <https://doi.org/10.1371/journal.pone.0144178>.
- [18] D. Raoult. Rapport de mission. <http://ifr48.timone.univ-mrs.fr/files/Documents-Raoult/bioterrorisme2003.pdf> 2003 Available from: URL: <http://ifr48.timone.univ-mrs.fr/files/Documents-Raoult/bioterrorisme2003.pdf>.
- [19] M. Salmon, D. Schumacher, M. Höhle, Monitoring Count Time Series in R: Aberration Detection in Public Health Surveillance, *Journal of Statistical Software* 70 (2016) 1–3, <https://doi.org/10.18637/jss.v070.i10>.
- [20] S. Amrane, H. Tissot-Dupont, B. Doudier, et al., Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, January 31st to March 1st, 2020: A respiratory virus snapshot, *Travel Med. Infect. Dis.* 36 (2020) 10163, <https://doi.org/10.1016/j.tmaid.2020.101632>.
- [21] C. Boschi, V.T. Hoang, A. Giraud-Gatineau, et al., Coinfections with SARS-CoV-2 and other respiratory viruses in Southeastern France: A matter of sampling time, *J. Med. Virol.* 93 (2021) 1878–1881, <https://doi.org/10.1002/jmv.26692>.
- [22] M. Huart, G. Bedubourg, C. Abat, P. Colson, et al., Implementation and initial analysis of a laboratory-based weekly biosurveillance system, Provence-Alpes-Côte d'Azur, France, *Emerg. Infect. Dis.* 23 (2017) 582–589, <https://doi.org/10.3201/eid2304.161399>.
- [23] R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/2019>.
- [24] K.H. Chu, N.J. Brown, A. Pelecanos, A.F. Brown, Simpson's paradox: A statistician's case study, *Emerg. Med. Australas.* 30 (2018) 431–433, <https://doi.org/10.1111/1742-6723.12943>.
- [25] Bulletin épidémiologique grippe, semaine 7. Saison 2020-2021, February 25, 2021. Retrieved from, <https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/grippe/documents/bulletin-national/bulletin-epidemiologique-grippe-semaine-7.-saison-2020-2021>.
- [26] N. Jones, How COVID-19 is changing the cold and flu season, *Nature* 588 (2020) 388–390, <https://doi.org/10.1038/d41586-020-03519-3>.
- [27] S.J. Olsen, E. Azziz-Baumgartner, A.P. Budd, et al., Decreased influenza activity during the COVID-19 pandemic - United States, Australia, Chile, and South Africa, 2020, *Morb. Mortal. Wkly Rep.* 69 (2020) 1305–1309, <https://doi.org/10.15585/mmwr.mm6937a6>.

- [28] K. Servick, COVID-19 measures also suppress flu-for now, *Science* 371 (2020) 224, <https://doi.org/10.1126/science.371.6526.224>.
- [29] Decree No. 2020-860 of 10 July 2020 prescribing general measures required to fight against the COVID-19 epidemic in regions where the health emergency has ended and those in which it has been prolonged. <https://www.legifrance.gouv.fr/loda/id/JORFTEXT000042105897/2020-07-11#JORFTEXT000042105897>.
- [30] M. Zuin, G. Rigatelli, G. Zuliani, L. Roncon, COVID-19 restrictive measures are changing the flu season in Italy, *Minerva Med.* 10 (2021), <https://doi.org/10.23736/S0026-4806.21.07359-6>, 2021 Feb 8 Online ahead of print.
- [31] E. Bendavid, C. Oh, J. Bhattacharya, J. Ioannidis, Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19, *Eur. J. Clin. Invest.* 51 (4) (2021) e13484, <https://doi.org/10.1111/eci.13484>.
- [32] Q. De Laroche Lambert, A. Marc, J. Antero, et al., Covid-19 mortality: A matter of vulnerability among nations facing limited margins of adaptation, *Front. Public Health* 8 (2020), 604339, <https://doi.org/10.3389/fpubh.2020.604339>.
- [33] A. Giraud-Gatineau, P. Colson, M.T. Jimeno, et al., Comparison of mortality associated with respiratory viral infections between December 2019 and March 2020 with that of the previous year in Southeastern France, *Int. J. Infect. Dis.* 96 (2020) 154–156, <https://doi.org/10.1016/j.ijid.2020.05.001>.
- [34] A. Hassanin, P. Grandcolas, G. Veron, Covid-19: natural or anthropic origin? *Mammalia* 85 (2021) 1–7, <https://doi.org/10.1515/mammalia-2020-0044>.
- [35] E.I. Patterson, G. Elia, A. Grassi, et al., Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy, *Nat. Comm.* 11 (2020) 6231, <https://doi.org/10.1038/s41467-020-20097-0>.
- [36] F. Fenollar, O. Mediannikov, M. Maurin, et al., Mink, SARS-CoV-2, and the human-animal interface, *Front. Microbiol.* 12 (2021), 663815, <https://doi.org/10.3389/fmicb.2021.663815>.
- [37] P. Colson, C.A. Devaux, J.C. Lagier, P. Gautret, D. Raoult, A possible role of remdesivir and plasma therapy in the selective sweep and emergence of new SARS-CoV-2 variants, *J. Clin. Med.* 10 (2021) 3276, <https://doi.org/10.3390/jcm10153276>.
- [38] C. Tanislav, K. Kostev, Fewer non-COVID-19 respiratory tract infections and gastrointestinal infections during the COVID-19 pandemic, *J. Med. Virol.* 94 (2022) 298–302, <https://doi.org/10.1002/jmv.27321>.
- [39] H. Agca, H. Akalin, I. Saglik, M. Hacimustafaoglu, S. Celebi, B. Ener, Changing epidemiology of influenza and other respiratory viruses in the first year of COVID-19 pandemic, *J. Infect. Public Health.* 14 (2021) 1186–1190, <https://doi.org/10.1016/j.jiph.2021.08.004>.
- [40] G. Ippolito, A. La Vecchia, G. Umbrello, et al., Disappearance of seasonal respiratory viruses in children under two years old during COVID-19 pandemic: A monocentric retrospective study in Milan, Italy, *Front. Pediatr.* 9 (2021), 721005, <https://doi.org/10.3389/fped.2021.721005>.
- [41] D.K. Yeoh, D.A. Foley, C.A. Minney-Smith, et al., Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter, *Clin. Infect. Dis.* 72 (2021) 2199–2202, <https://doi.org/10.1093/cid/ciaa1475>.
- [42] R.J.J. Soo, C.J. Chiew, S. Ma, R. Pung, V. Lee, Decreased influenza incidence under COVID-19 control measures, Singapore, *Emerg. Infect. Dis.* 26 (2020) 1933–1935, <https://doi.org/10.1016/j.tmaid.2021.102057>.
- [43] N.P. Jewell, J.A. Lewnard, B.L. Jewell, Predictive mathematical models of the COVID-19 pandemic: Underlying principles and value of projections, *JAMA* 323 (2020) 1893–1894, <https://doi.org/10.1001/jama.2020.6585>.
- [44] M.D. Christian, S.M. Poutanen, M.R. Loutfy, et al., Severe acute respiratory syndrome, *Clin. Infect. Dis.* 38 (2004) 1420–1427, <https://doi.org/10.1086/420743>.
- [45] C. Del Rio, S.B. Omer, P.N. Malani, Winter of Omicron - The evolving COVID-19 pandemic, *JAMA* 327 (2021) 319–320, <https://doi.org/10.1001/jama.2021.24315>.